Faculty Opinions recommendation of A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Oncology Group ◽

Oncology Group Study ◽

Bibf 1120

A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.10.001 ◽

2014 ◽

Vol 135 (3) ◽

pp. 441-445 ◽

Cited By ~ 38

Author(s):

Don S. Dizon ◽

Michael W. Sill ◽

Jeanne M. Schilder ◽

Kathryn F. McGonigle ◽

Zia Rahman ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Oncology Group Study ◽

Bibf 1120

A phase II evaluation of AZD6244, a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.04.086 ◽

2013 ◽

Vol 130 (1) ◽

pp. e12-e13 ◽

Cited By ~ 5

Author(s):

R. Coleman ◽

M. Sill ◽

P. Thaker ◽

K. De Geest ◽

D. Street ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5592 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5592-5592 ◽

Cited By ~ 2

Author(s):

Andrea P. Myers ◽

Virginia L. Filiaci ◽

Yuping Zhang ◽

Michael Pearl ◽

Kian Behbakht ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Mutational Analysis ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Megestrol Acetate ◽

Oncology Group ◽

Faculty Opinions recommendation of A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718491022.793527266 ◽

2017 ◽

Author(s):

Paola Gehrig

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2007.01.019 ◽

2007 ◽

Vol 105 (2) ◽

pp. 508-516 ◽

Cited By ~ 71

Author(s):

D. Scott McMeekin ◽

Michael W. Sill ◽

Doris Benbrook ◽

Kathleen M. Darcy ◽

Deborah J. Stearns-Kurosawa ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2015.04.005 ◽

2015 ◽

Vol 138 (1) ◽

pp. 30-35 ◽

Cited By ~ 36

Author(s):

Robert L. Coleman ◽

Michael W. Sill ◽

Premal H. Thaker ◽

David P. Bender ◽

Daron Street ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

Corrigendum to “A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study” [Gynecol Oncol 127 (2012) 538–543]

Gynecologic Oncology ◽

10.1016/j.ygyno.2013.04.007 ◽

2013 ◽

Vol 130 (1) ◽

pp. 252-253 ◽

Cited By ~ 2

Author(s):

Robert L. Coleman ◽

Michael W. Sill ◽

Heather A. Lankes ◽

Amanda Nickles Fader ◽

Neil J. Finkler ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽

A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.07.083 ◽

2014 ◽

Vol 135 (1) ◽

pp. 38-43 ◽

Cited By ~ 56

Author(s):

Matthew A. Powell ◽

Michael W. Sill ◽

Paul J. Goodfellow ◽

Doris M. Benbrook ◽

Heather A. Lankes ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Gynecologic Oncology ◽

Oncology Group ◽

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2016.02.025 ◽

2016 ◽

Vol 141 (1) ◽

pp. 43-48 ◽

Cited By ~ 13

Author(s):

Andrea P. Myers ◽

Virginia L. Filiaci ◽

Yuping Zhang ◽

Michael Pearl ◽

Kian Behbakht ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Mutational Analysis ◽

Phase Ii Study ◽

Gynecologic Oncology ◽

Megestrol Acetate ◽

Oncology Group ◽

A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2012.08.020 ◽

2012 ◽

Vol 127 (3) ◽

pp. 538-543 ◽

Cited By ~ 56

Author(s):

Robert L. Coleman ◽

Michael W. Sill ◽

Heather A. Lankes ◽

Amanda Nickles Fader ◽

Neil J. Finkler ◽

...

Keyword(s):

Endometrial Cancer ◽

Phase Ii ◽

Gynecologic Oncology ◽

Oncology Group ◽